University Of Alabama At Birmingham
- CTSA Program HubCenter for Clinical and Translational Science
This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. The study is a multicenter trial that will be conducted in up to approximately 100 sites globally. The study will compare different investigational therapeutic agents to a control arm. There will be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). Any such change would be accompanied by an updated sample size. Because background standards of supportive care may evolve/improve over time as more is learned about successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized subjects. An independent Data and Safety Monitoring Board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms. To evaluate the clinical efficacy, as assessed by time to recovery, of different investigational therapeutics as compared to the control arm.Whether 200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course, can reduce severity of COVID-19 illness and/or improve time to recovery when compared with placebo.Target PopulationInclusion Criteria:
Admitted to a hospital with symptoms suggestive of COVID-19 infection.
Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.
Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.
Male or non-pregnant female adult > / = 18 years of age at time of enrollment.
Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen, as documented by either or the following:
PCR positive in sample collected < 72 hours prior to randomization; OR
PCR positive in sample collected >/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection.
Illness of any duration, and at least one of the following:
Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR
SpO2 < / = 94% on room air, OR
Requiring supplemental oxygen, OR
Requiring mechanical ventilation.
Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.
Agrees to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 through Day 29.
Alanine Transaminase (ALT) or Aspartate Transaminase (AST) > 5 times the upper limit of normal.
Estimated glomerular filtration rate (eGFR) < 30 ml/min (including patients receiving hemodialysis or hemofiltration).
Pregnancy or breast feeding.
Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours.
Allergy to any study medication.Contact EmailStudy TypeTreatments and InterventionsClinicaltrials.gov StatusSubmitted to clinicaltrials.govClinicalTrials.gov IdentifierNCT04280705Current Study StatusRecruitingCurrent Study PhasePhase 3Clinical Trial Network UtilizationYesVaccine Trial Evaluation UnitAccrual Target Number572CTSA SupportNo
Self-Care in the COVID Era
- Regional Consortia
Southeast Health Alliance For Research
- Educational Content
Statistical Topics for Reproducible Animal ResearchIndiana UniversityUniversity Of Alabama At BirminghamNational Institutes of Health
- Consortium News
The CTSA External Reviewer Exchange Consortium (CEREC): Engagement and Efficacy
Translational Training Symposium
CCTS Genomic Medicine & Precision TherapeuticsUniversity Of Alabama At Birmingham
University of Alabama at Birmingham Aging Symposium
I-Corps Regional Short Course Returns to CCTS Hub this Summer
I-Corps: bridging biomedical innovation and the marketEmployer/Host
UAB/Children’s of Alabama/School of Health ProfessionsEmployer/Host
UAB/Children’s pediatric simulation centerEmployer/Host
UAB Pharmacoepidemiology and Economic Research (PEER) UnitEmployer/Host
Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)Employer/Host
Phase I clinical trials/public-private partnershipsEmployer/Host
Clinical Informatics / medical systemsEmployer/Host
Cochrane Musculoskeletal Review GroupEmployer/Host
Alliance for Innovative Medical Technology (AIMTech)/medical device development (R. Hergenrother, PhD)Employer/Host